New York State Teachers Retirement System Purchases 21,976 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

New York State Teachers Retirement System lifted its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 24.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 113,090 shares of the biotechnology company’s stock after acquiring an additional 21,976 shares during the period. New York State Teachers Retirement System’s holdings in ADMA Biologics were worth $1,939,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ADMA. Hollencrest Capital Management purchased a new stake in ADMA Biologics during the 3rd quarter valued at $30,000. Larson Financial Group LLC bought a new stake in ADMA Biologics during the third quarter valued at about $31,000. GAMMA Investing LLC increased its position in ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after buying an additional 967 shares in the last quarter. National Bank of Canada FI bought a new position in shares of ADMA Biologics in the third quarter worth about $35,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of ADMA Biologics during the 3rd quarter valued at about $62,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

ADMA has been the subject of several analyst reports. HC Wainwright increased their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Raymond James upped their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $15.84 on Friday. The stock has a 50-day moving average price of $16.97 and a 200 day moving average price of $17.95. The stock has a market capitalization of $3.74 billion, a P/E ratio of 56.57 and a beta of 0.75. ADMA Biologics, Inc. has a 12-month low of $5.08 and a 12-month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.